Prescribing to protect case series: naltrexone as a novel intervention to prevent fentanyl overdose in people who use cocaine.
- 1Department of Family Medicine, Boston Medical Center, 801 Massachusetts Avenue Boston, Boston, MA, 02118, USA. [email protected].
- 2Department of Medicine, Section of General Internal Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA, USA.
- 3Department of Family Medicine, Boston Medical Center, 801 Massachusetts Avenue Boston, Boston, MA, 02118, USA.
Abstract
Background
The rise in fentanyl contamination of cocaine has contributed to a surge in opioid-involved overdose deaths among people who use cocaine (PWUC). Existing harm reduction strategies, including naloxone distribution, drug checking, and counseling people to use with others, are inadequate in fully addressing this risk. Despite robust evidence supporting contingency management (CM) as an effective treatment for cocaine use disorder (CUD), its implementation remains limited. Naltrexone, a potent opioid antagonist, has been evaluated for treatment of CUD and has not been found to be effective. No pharmacotherapies are FDA approved for CUD. However, naltrexone may provide opioid overdose protection for individuals at risk of unwitting fentanyl exposure through fentanyl contamination of cocaine.Case presentation
We conducted a retrospective case series of three adults with cocaine use disorder receiving care at the Stimulant Treatment and Recovery Team (START) Clinic at Boston Medical Center. All three patients with cocaine use disorder reported cocaine use with unintentional fentanyl exposure, and two had prior nonfatal opioid-involved overdoses. Oral or intramuscular naltrexone was initiated in all cases and was tolerated without reported adverse effects or precipitated withdrawal. Patients continued naltrexone for several months, and no opioid-involved overdoses were reported.Conclusions
In this case series of patients with cocaine use disorder, the initiation of naltrexone for opioid overdose risk prevention was feasible, acceptable, and well tolerated. Naltrexone warrants study as a component of overdose prevention strategies in stimulant treatment settings where fentanyl contamination poses increased risk.
Related
- Pharmacokinetics of xylazine and fentanyl in patients presenting to the emergency department after non-fatal opioid overdose
- An adapted enhanced social prescribing intervention vs. usual care in the treatment of loneliness in cancer survivors: Study protocol for a feasibility pilot randomized controlled trial
- Comparative efficacy of naltrexone-accelerated versus sublingual buprenorphine in opioid withdrawal management and initiating injectable naltrexone treatment: study protocol for a randomized controlled trial.
- Low Dose Naltrexone for Post-COVID Fatigue Syndrome: A Randomized Controlled Trial
- Double-blind, placebo-controlled randomised clinical trial on flexible doses of escitalopram and naltrexone in the treatment of men with compulsive sexual behaviour disorder: study protocol presentation
BibTeX
@article{xue2026prescribing,
title = {{Prescribing to protect case series: naltrexone as a novel intervention to prevent fentanyl overdose in people who use cocaine.}},
author = {Rachel Xue and Justin Alves and Marielle Baldwin and Jiarui Zhang and Colleen Labelle and Alexander Y Walley},
journal = {Addiction science \& clinical practice},
year = {2026},
month = jul,
doi = {10.1186/s13722-026-00701-2},
url = {https://europepmc.org/article/MED/42894254},
note = {CC BY},
}
RIS
TY - JOUR
TI - Prescribing to protect case series: naltrexone as a novel intervention to prevent fentanyl overdose in people who use cocaine.
AU - Rachel Xue
AU - Justin Alves
AU - Marielle Baldwin
AU - Jiarui Zhang
AU - Colleen Labelle
AU - Alexander Y Walley
PY - 2026
DA - 2026/07/01
JO - Addiction science & clinical practice
DO - 10.1186/s13722-026-00701-2
UR - https://europepmc.org/article/MED/42894254
AB - Background The rise in fentanyl contamination of cocaine has contributed to a surge in opioid-involved overdose deaths among people who use cocaine (PWUC). Existing harm reduction strategies, including naloxone distribution, drug checking, and counseling people to use with others, are inadequate in fully addressing this risk. Despite robust evidence supporting contingency management (CM) as an effective treatment for cocaine use disorder (CUD), its implementation remains limited. Naltrexone, a potent opioid antagonist, has been evaluated for treatment of CUD and has not been found to be effective. No pharmacotherapies are FDA approved for CUD. However, naltrexone may provide opioid overdose protection for individuals at risk of unwitting fentanyl exposure through fentanyl contamination of cocaine.Case presentation We conducted a retrospective case series of three adults with cocaine use disorder receiving care at the Stimulant Treatment and Recovery Team (START) Clinic at Boston Medical Center. All three patients with cocaine use disorder reported cocaine use with unintentional fentanyl exposure, and two had prior nonfatal opioid-involved overdoses. Oral or intramuscular naltrexone was initiated in all cases and was tolerated without reported adverse effects or precipitated withdrawal. Patients continued naltrexone for several months, and no opioid-involved overdoses were reported.Conclusions In this case series of patients with cocaine use disorder, the initiation of naltrexone for opioid overdose risk prevention was feasible, acceptable, and well tolerated. Naltrexone warrants study as a component of overdose prevention strategies in stimulant treatment settings where fentanyl contamination poses increased risk.
SN - 1940-0632
SN - 1940-0640
ER -